<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469883</url>
  </required_header>
  <id_info>
    <org_study_id>XNTK-I-03</org_study_id>
    <nct_id>NCT02469883</nct_id>
  </id_info>
  <brief_title>A Study of Sinotecean on Tolerance and Pharmacokinetics</brief_title>
  <official_title>A Phase I Study of Sinotecean on Tolerance and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity
      (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of
      Sinotecean.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments for Area Under Curve（AUC）</measure>
    <time_frame>Day 1-2 Single Dose</time_frame>
    <description>To collect point with single drug:5 min/10 min/15 min/30 min/1 h/2h/4h/6 h/8h/10h/12 h/24 h/32h/48 h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments for Cmax</measure>
    <time_frame>Day 1-2 Single Dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments for Tmax</measure>
    <time_frame>Day 1-2 Single Dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate （ORR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or progression of disease（PD） (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose(MTD)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicity(DLT)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Sinotecean</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinotecean</intervention_name>
    <arm_group_label>Sinotecean</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  late malignant tumor patients diagnosed with the pathological and/or cytological;

          -  lack of the standard treatment or treatment failure;

          -  18-65years, ECOG:0-1,expected survival period &gt;3 months;

          -  main organs function is normal;

          -  signed and dated informed consent

        Exclusion Criteria:

          -  participated in other clinical trials in four weeks;

          -  currently under other effective treatment;

          -  end of anti-tumor treatment within 4 weeks(end of Nitrosourea/Mitomycin within 6
             weeks);

          -  AE ≥ Grade 2(according to NCI-CTC 4.0),except hair loss;

          -  with ischemic heart disease, heart failure, severe arrhythmia, cerebrovascular
             disease, asthma, severe infections, active peptic ulcer;

          -  urine protein: ++, and urinary in 24 hours &gt; 1.0g;

          -  uncontrolled primary or metastatic brain;

          -  have immunodeficiency history;

          -  according to the researcher's judgment,there are concomitant diseases which will
             seriously endanger the patients or obstruct the patients to complete the clinical
             trial;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shusen Wang, doctor</last_name>
    <email>wangshs@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shusen Wang, doctor</last_name>
      <email>wangshs@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

